From Diabetes to Weight Loss: The Problems with Semaglutide's Expanded Use

From Diabetes to Weight Loss: The Problems with Semaglutide's Expanded Use

Saved in:

Bibliographic Details
Main Author:	Rawan Othman
Format:	Article
Language:	English
Published:	University of Ottawa 2025-08-01
Series:	University of Ottawa Journal of Medicine
Subjects:	semaglutide diabetes weight loss
Online Access:	https://uottawa.scholarsportal.info/ottawa/index.php/uojm-jmuo/article/view/7533
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta‐Analysis of Direct Comparative Studies
by: Jimmy Wen, et al.
Published: (2025-05-01)

Race of GLPS: Impact on Weight and Glycemic Control on Type 2 Diabetes with Semaglutide Versus Liraglutide
by: Noha Hafeez, et al.
Published: (2024-12-01)

Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
by: Louis Talay, et al.
Published: (2024-10-01)

Alopecia areata following semaglutide treatment for weight loss: A case report
by: Wasan S. Alzahrani, MBBS, et al.
Published: (2025-09-01)

Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in Adults with and Without Type 2 Diabetes: A Systematic Review and Meta-Analysis
by: Boram Hong, et al.
Published: (2025-07-01)

Spotlight on the Mechanism of Action of Semaglutide
by: Ilias Papakonstantinou, et al.
Published: (2024-12-01)

Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
by: Rui Salvador, et al.
Published: (2025-03-01)

Effects of semaglutide in patients with chronic ankle instability: evidence from a prospective cohort
by: Jieyuan Zhang, et al.
Published: (2025-03-01)

Real-World Effectiveness of Oral Semaglutide in Indian Adult Diabetic Patients: Evaluation of EMR-based Data
by: Sandeep Gudibanda, et al.
Published: (2024-10-01)

Semaglutide and High-Intensity Interval Exercise Attenuate Cognitive Impairment in Type 2 Diabetic Mice via BDNF Modulation
by: Sijie Lai, et al.
Published: (2025-05-01)

Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01)

Real‐World Persistence and Characteristics of Type 2 Diabetes Patients Prescribed Semaglutide in Scotland
by: David Alexander Dickie, et al.
Published: (2025-05-01)

Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data
by: Marine Massy, et al.
Published: (2025-04-01)

SEMAGLUTIDE: Weight loss, glycaemic control and safety profile in obese patients with and without type-II diabetes-An experience from Karachi, Pakistan
by: Muhammad Y. Memon, et al.
Published: (2024-10-01)

Oral semaglutide: the innovation in type 2 diabetes management
by: M. V. Shestakova, et al.
Published: (2021-09-01)

Recommendations for Titration and Administration of Oral Semaglutide for the Treatment of Type 2 Diabetes during Ramadan
by: Mohamed Hassanein, et al.
Published: (2022-12-01)

Non-Arteritic Anterior Ischemic Optic Neuropathy in an Otherwise Healthy Young Adult Patient Treated with Liraglutide and Semaglutide for Weight Loss: A Cautionary Tale
by: Lixi F, et al.
Published: (2025-08-01)

Semaglutide in people with obesity and type 2 diabetes on hemodialysis: a prospective analysis of glycemic and weight outcomes
by: Akinori Hayashi, et al.
Published: (2025-05-01)

Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis
by: Rui Wu, et al.
Published: (2025-08-01)

Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study
by: Anders Boisen Jensen, et al.
Published: (2025-04-01)

Contractile Effects of Semaglutide in the Human Atrium
by: Joachim Neumann, et al.
Published: (2024-08-01)

Semaglutide: an emerging treatment option for patients with obesity related HFpEF
by: Sanya Ashraf Khaskheli, et al.
Published: (2024-08-01)

Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes
by: Mohamad Suki, et al.
Published: (2025-07-01)

Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide
by: Peter Bracha, et al.
Published: (2024-12-01)

Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study
by: Ren Q, et al.
Published: (2025-07-01)

The impact of oral semaglutide on glycemic control and weight reduction: a database analysis of dosing effects in Japanese individuals with type 2 diabetes
by: Mizuki Ishiguro, et al.
Published: (2025-08-01)

Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report
by: Kenneth Brand, et al.
Published: (2025-04-01)

Semaglutide and human reproduction: caution at the intersection of energy balance, ovarian function, and follicular development
by: E. Scott Sills, et al.
Published: (2025-08-01)

A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait
by: Saleh Alali, et al.
Published: (2025-05-01)

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial
by: Jelena Petković-Dabić, et al.
Published: (2025-01-01)

Efficacy and safety of oral semaglutide in Russian patients with type 2 diabetes: subgroup analysis of PIONEER 1, 2, 3 trials
by: M. Sh. Shamkhalova, et al.
Published: (2022-07-01)

Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes
by: Junko Oya, et al.
Published: (2025-04-01)

Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland
by: Hoffmann K, et al.
Published: (2025-08-01)

Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2
by: Yang L, et al.
Published: (2024-11-01)

Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin–Lipid Conjugate-Based Nanoparticle
by: Kyeong-Ju Lee, et al.
Published: (2025-04-01)

Weight Gain, Weight Loss, and Type 2 Diabetes Risk: Evidence From the Atherosclerosis Risk in Communities (ARIC) Study
by: Samaneh Asgari, et al.
Published: (2025-05-01)

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01)

Echoes of Dormancy: Anomic Aphasia Unveils Neurocysticercosis Reactivation in a Patient on Semaglutide
by: Marcos Osorio Borjas, et al.
Published: (2025-05-01)

Semaglutide and adenosine alleviate obesity-induced kidney injury, with observed modulation of the Txnip/NLRP3 pathway
by: Shuqi Wang, et al.
Published: (2025-05-01)

Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial
by: Haiyan Chen, et al.
Published: (2025-07-01)